From the Department of Neurology (S.E.S., Y.L., V.D.B., A.M.F., D.M.H., R.J.B., J.C.M.), Knight Alzheimer Disease Research Center (S.E.S., V.D.B., B.A.G., T.L.S.B., G.W., D.C., A.M.F., D.M.H., R.J.B., J.C.M., C.X.), Division of Biostatistics (Y.L., G.W., D.C., C.X.), Mallinckrodt Institute of Radiology (B.A.G., T.L.S.B.), and Hope Center for Neurological Disorders (A.M.F., D.M.H., R.J.B.), Washington University School of Medicine, St. Louis, MO; and Department of Neurology and Psychiatry (W.E.K.), University of Pittsburgh, PA.
Neurology. 2021 Nov 2;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 9.
To predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).
Brain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR) was transformed into a timescale with the use of longitudinal data.
Amyloid accumulation was evaluated in 236 individuals who underwent >1 amyloid PET scan. The average age was 66.5 ± 9.2 years, and 12 individuals (5%) had cognitive impairment at their baseline amyloid PET scan. A tipping point in amyloid accumulation was identified at a low level of amyloid burden (SUVR 1.2), after which nearly all individuals accumulated amyloid at a relatively consistent rate until reaching a high level of amyloid burden (SUVR 3.0). The average time between levels of amyloid burden was used to estimate the age at which an individual reached SUVR 1.2. Longitudinal clinical diagnoses for 180 individuals were aligned by the estimated age at SUVR 1.2. In the 22 individuals who progressed from cognitively normal to a typical AD dementia syndrome, the estimated age at which an individual reached SUVR 1.2 predicted the age at symptom onset ( = 0.54, < 0.0001, root mean square error [RMSE] 4.5 years); the model was more accurate after exclusion of 3 likely misdiagnoses ( = 0.84, < 0.0001, RMSE 2.8 years).
The age at symptom onset in sporadic AD is strongly correlated with the age at which an individual reaches a tipping point in amyloid accumulation.
预测脑淀粉样变但认知正常的个体何时会出现阿尔茨海默病(AD)的症状。
采用匹兹堡化合物 B 进行淀粉样蛋白 PET 测量脑淀粉样蛋白负担。平均皮质标准化摄取值比(SUVR)通过使用纵向数据转换为时间尺度。
对 236 名接受 >1 次淀粉样蛋白 PET 扫描的个体进行了淀粉样蛋白积聚评估。平均年龄为 66.5 ± 9.2 岁,12 名个体(5%)在基线淀粉样蛋白 PET 扫描时存在认知障碍。在低淀粉样蛋白负担水平(SUVR 1.2)时确定了淀粉样蛋白积聚的转折点,此后,几乎所有个体的淀粉样蛋白积聚速度都相对一致,直到达到高淀粉样蛋白负担水平(SUVR 3.0)。使用淀粉样蛋白负担水平之间的平均时间来估计个体达到 SUVR 1.2 的年龄。通过估计的 SUVR 1.2 年龄将 180 名个体的纵向临床诊断对齐。在从认知正常进展为典型 AD 痴呆综合征的 22 名个体中,个体达到 SUVR 1.2 的估计年龄预测了症状发作的年龄( = 0.54,<0.0001,均方根误差 [RMSE] 4.5 年);排除 3 例可能误诊后,该模型更准确( = 0.84,<0.0001,RMSE 2.8 年)。
散发型 AD 的发病年龄与个体达到淀粉样蛋白积聚转折点的年龄密切相关。